Mangoceuticals

MGRX · NASDAQ

$0.30+$0.0199 (+7.10%)TodayMarket closed ·
Prev close $0.2801

About MGRX

Mangoceuticals, Inc. engages in developing, marketing, and selling men's wellness products and services via a telemedicine platform. The company is headquartered in Dallas, Texas. The company went IPO on 2023-03-21. The company is advancing its proprietary antiviral compound MGX-0024. The firm offers pharmaceutical-based products specifically related to the treatments of erectile dysfunction (ED), hair growth, hormone replacement therapies, and weight management. The company has developed and is commercially marketing a brand of ED products under the brand name Mango; a brand of hair loss products under the brand name Grow; a brand of hormone balance and therapy products under the name Mojo, and a brand of weight loss products under the brand name Slim. Prime by MangoRx is a TRT product available by prescription. The Mango ED product includes the three ingredients: Either Sildenafil (the active ingredient in Viagra) or Tadalafil (the active ingredient in Cialis), and Oxytocin.

Employees
0
Headquarters
Dallas, Texas
Listed
Mar 21, 2023
Sector
Consumer Staples
Industry
Consumer Staples Distribution & Retail

Leadership

Mangoceuticals executives
NameTitleSince
Jacob Cohen—2021
Eugene Johnston——
Lorraine Dalessio——
Alex Hamilton——
Kenny Myers——

Similar companies

Companies in the same industry as Mangoceuticals

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.